These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19147777)

  • 1. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
    Broniscer A; Baker SJ; Stewart CF; Merchant TE; Laningham FH; Schaiquevich P; Kocak M; Morris EB; Endersby R; Ellison DW; Gajjar A
    Clin Cancer Res; 2009 Jan; 15(2):701-7. PubMed ID: 19147777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
    Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
    J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
    Geoerger B; Hargrave D; Thomas F; Ndiaye A; Frappaz D; Andreiuolo F; Varlet P; Aerts I; Riccardi R; Jaspan T; Chatelut E; Le Deley MC; Paoletti X; Saint-Rose C; Leblond P; Morland B; Gentet JC; Méresse V; Vassal G;
    Neuro Oncol; 2011 Jan; 13(1):109-18. PubMed ID: 20974795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
    Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
    Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
    J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
    J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
    Christiansen SR; Broniscer A; Panetta JC; Stewart CF
    Pharmacotherapy; 2009 Jul; 29(7):858-66. PubMed ID: 19558260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
    Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
    Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
    Hughes AN; O'Brien ME; Petty WJ; Chick JB; Rankin E; Woll PJ; Dunlop D; Nicolson M; Boinpally R; Wolf J; Price A
    J Clin Oncol; 2009 Mar; 27(8):1220-6. PubMed ID: 19164205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
    White-Koning M; Civade E; Geoerger B; Thomas F; Le Deley MC; Hennebelle I; Delord JP; Chatelut E; Vassal G
    Clin Cancer Res; 2011 Jul; 17(14):4862-71. PubMed ID: 21653689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
    Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE
    Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
    Macpherson IR; Poondru S; Simon GR; Gedrich R; Brock K; Hopkins CA; Stewart K; Stephens A; Evans TR
    Eur J Cancer; 2013 Mar; 49(4):782-9. PubMed ID: 23099006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
    Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
    Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
    J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.